Polymer nanoparticles have emerged as transformative tools at the interface of nanotechnology and biomedicine, driven by advances in nanoengineering that enable precise control over their size, shape, and surface functionality. This chapter critically explores how these engineered particles traverse biological barriers and respond to complex physiological cues, transforming passive carriers into dynamic agents for targeted therapy, diagnostics, and real, time monitoring. Key design strategies such as emulsion polymerization, nanoprecipitation, and microfluidics enable tunable control over particle architecture, while surface modifications, through ligand conjugation, PEGylation, and zwitterionic coatings, extend circulation times and enhance targeting precision. Responsive and smart polymers, capable of reacting to pH, redox potential, and enzymatic activity, and innovations like “sheddable” stealth coatings further improve site, specific delivery. Core–shell and multilayer architectures, assembled via techniques like layer, by, layer deposition and hybrid inorganic–polymer design, integrate therapeutic and imaging functions within single nano systems. Case studies highlight their practical translation: crossing the blood–brain barrier with ligand, targeted carriers, leveraging the EPR effect in tumours, penetrating mucosal barriers, and overcoming endosomal entrapment to deliver payloads directly into the cytosol. Applications extend from targeted drug and gene delivery, including siRNA, mRNA, and CRISPR systems, to theranostics and biosensing platforms capable of real, time disease monitoring. Despite these advances, challenges in reproducibility, large, scale manufacturing, and in vitro versus in vivo discrepancies remain significant hurdles. Emerging trends such as AI, guided nanoparticle design, biomimetic and programmable particles, and a stronger integration of data science promise to bridge these gaps, propelling the field toward truly personalised and adaptive nanomedicine. Ultimately, the future success of polymer nanoparticles relies on interdisciplinary collaboration bringing together chemists, engineers, clinicians, and regulatory scientists to translate laboratory breakthroughs into safe, scalable, and clinically effective therapies, reshaping the paradigm of diagnosis and treatment in modern medicine.